Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy

Frances A. Shepherd, Janet Dancey, Rodryg Ramlau, Karin Mattson, Richard J. Gralla, Mark O'Rourke, Nathan Levitan, Laurent Gressot, Mark Vincent, Ronald Burkes, Susan Coughlin, Yong Kim, Jocelyne Berille

Research output: Contribution to journalArticle

1914 Citations (Scopus)

Abstract

Purpose: To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung cancer who had previously been treated with platinum- based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life. Patients and Methods: Patients with performance statuses of 0 to 2 and stage IIIB/IV non-small-cell lung cancer with either measurable or evaluable lesions were eligible for entry onto the study if they had undergone one or more platinum-based chemotherapy regimens and if they had adequate hematology and biochemistry parameters. They were excluded if they had symptomatic brain metastases or if they had previously been treated with paclitaxel. Patients were stratified by performance status and best response to cisplatin chemotherapy and were then randomized to treatment with docetaxel 100 mg/m2 (49 patients) or 75 mg/m2 (55 patients) or best supportive care. Patients in both arms were assessed every 3 weeks. Results: One hundred four patients (103 of whom were eligible for entry onto the study) were well balanced for prognostic factors. Of 84 patients with measurable lesions, six (7.1%) achieved partial responses (three patients at each dose level). Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P < .001), as was median survival (7.0 v 4.6 months; log-rank test, P = .047). The difference was more significant for docetaxel 75 mg/m2 patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P = .010; 1-year survival, 37% v 11%; χ2 test, P = .003). Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m2, three of whom died, and in one patient treated with docetaxel 75 mg/m2. Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups. Conclusion: Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m2, the benefits of docetaxel therapy outweigh the risks. (C) 2000 American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)2095-2103
Number of pages9
JournalJournal of Clinical Oncology
Volume18
Issue number10
StatePublished - May 2000
Externally publishedYes

Fingerprint

docetaxel
Platinum
Non-Small Cell Lung Carcinoma
Patient Care
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R. J., O'Rourke, M., ... Berille, J. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy. Journal of Clinical Oncology, 18(10), 2095-2103.

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy. / Shepherd, Frances A.; Dancey, Janet; Ramlau, Rodryg; Mattson, Karin; Gralla, Richard J.; O'Rourke, Mark; Levitan, Nathan; Gressot, Laurent; Vincent, Mark; Burkes, Ronald; Coughlin, Susan; Kim, Yong; Berille, Jocelyne.

In: Journal of Clinical Oncology, Vol. 18, No. 10, 05.2000, p. 2095-2103.

Research output: Contribution to journalArticle

Shepherd, FA, Dancey, J, Ramlau, R, Mattson, K, Gralla, RJ, O'Rourke, M, Levitan, N, Gressot, L, Vincent, M, Burkes, R, Coughlin, S, Kim, Y & Berille, J 2000, 'Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy', Journal of Clinical Oncology, vol. 18, no. 10, pp. 2095-2103.
Shepherd, Frances A. ; Dancey, Janet ; Ramlau, Rodryg ; Mattson, Karin ; Gralla, Richard J. ; O'Rourke, Mark ; Levitan, Nathan ; Gressot, Laurent ; Vincent, Mark ; Burkes, Ronald ; Coughlin, Susan ; Kim, Yong ; Berille, Jocelyne. / Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 10. pp. 2095-2103.
@article{043396746cc44501ba6f8e91d4015c30,
title = "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy",
abstract = "Purpose: To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung cancer who had previously been treated with platinum- based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life. Patients and Methods: Patients with performance statuses of 0 to 2 and stage IIIB/IV non-small-cell lung cancer with either measurable or evaluable lesions were eligible for entry onto the study if they had undergone one or more platinum-based chemotherapy regimens and if they had adequate hematology and biochemistry parameters. They were excluded if they had symptomatic brain metastases or if they had previously been treated with paclitaxel. Patients were stratified by performance status and best response to cisplatin chemotherapy and were then randomized to treatment with docetaxel 100 mg/m2 (49 patients) or 75 mg/m2 (55 patients) or best supportive care. Patients in both arms were assessed every 3 weeks. Results: One hundred four patients (103 of whom were eligible for entry onto the study) were well balanced for prognostic factors. Of 84 patients with measurable lesions, six (7.1{\%}) achieved partial responses (three patients at each dose level). Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P < .001), as was median survival (7.0 v 4.6 months; log-rank test, P = .047). The difference was more significant for docetaxel 75 mg/m2 patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P = .010; 1-year survival, 37{\%} v 11{\%}; χ2 test, P = .003). Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m2, three of whom died, and in one patient treated with docetaxel 75 mg/m2. Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups. Conclusion: Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m2, the benefits of docetaxel therapy outweigh the risks. (C) 2000 American Society of Clinical Oncology.",
author = "Shepherd, {Frances A.} and Janet Dancey and Rodryg Ramlau and Karin Mattson and Gralla, {Richard J.} and Mark O'Rourke and Nathan Levitan and Laurent Gressot and Mark Vincent and Ronald Burkes and Susan Coughlin and Yong Kim and Jocelyne Berille",
year = "2000",
month = "5",
language = "English (US)",
volume = "18",
pages = "2095--2103",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy

AU - Shepherd, Frances A.

AU - Dancey, Janet

AU - Ramlau, Rodryg

AU - Mattson, Karin

AU - Gralla, Richard J.

AU - O'Rourke, Mark

AU - Levitan, Nathan

AU - Gressot, Laurent

AU - Vincent, Mark

AU - Burkes, Ronald

AU - Coughlin, Susan

AU - Kim, Yong

AU - Berille, Jocelyne

PY - 2000/5

Y1 - 2000/5

N2 - Purpose: To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung cancer who had previously been treated with platinum- based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life. Patients and Methods: Patients with performance statuses of 0 to 2 and stage IIIB/IV non-small-cell lung cancer with either measurable or evaluable lesions were eligible for entry onto the study if they had undergone one or more platinum-based chemotherapy regimens and if they had adequate hematology and biochemistry parameters. They were excluded if they had symptomatic brain metastases or if they had previously been treated with paclitaxel. Patients were stratified by performance status and best response to cisplatin chemotherapy and were then randomized to treatment with docetaxel 100 mg/m2 (49 patients) or 75 mg/m2 (55 patients) or best supportive care. Patients in both arms were assessed every 3 weeks. Results: One hundred four patients (103 of whom were eligible for entry onto the study) were well balanced for prognostic factors. Of 84 patients with measurable lesions, six (7.1%) achieved partial responses (three patients at each dose level). Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P < .001), as was median survival (7.0 v 4.6 months; log-rank test, P = .047). The difference was more significant for docetaxel 75 mg/m2 patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P = .010; 1-year survival, 37% v 11%; χ2 test, P = .003). Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m2, three of whom died, and in one patient treated with docetaxel 75 mg/m2. Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups. Conclusion: Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m2, the benefits of docetaxel therapy outweigh the risks. (C) 2000 American Society of Clinical Oncology.

AB - Purpose: To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung cancer who had previously been treated with platinum- based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life. Patients and Methods: Patients with performance statuses of 0 to 2 and stage IIIB/IV non-small-cell lung cancer with either measurable or evaluable lesions were eligible for entry onto the study if they had undergone one or more platinum-based chemotherapy regimens and if they had adequate hematology and biochemistry parameters. They were excluded if they had symptomatic brain metastases or if they had previously been treated with paclitaxel. Patients were stratified by performance status and best response to cisplatin chemotherapy and were then randomized to treatment with docetaxel 100 mg/m2 (49 patients) or 75 mg/m2 (55 patients) or best supportive care. Patients in both arms were assessed every 3 weeks. Results: One hundred four patients (103 of whom were eligible for entry onto the study) were well balanced for prognostic factors. Of 84 patients with measurable lesions, six (7.1%) achieved partial responses (three patients at each dose level). Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P < .001), as was median survival (7.0 v 4.6 months; log-rank test, P = .047). The difference was more significant for docetaxel 75 mg/m2 patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P = .010; 1-year survival, 37% v 11%; χ2 test, P = .003). Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m2, three of whom died, and in one patient treated with docetaxel 75 mg/m2. Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups. Conclusion: Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m2, the benefits of docetaxel therapy outweigh the risks. (C) 2000 American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0034069620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034069620&partnerID=8YFLogxK

M3 - Article

C2 - 10811675

AN - SCOPUS:0034069620

VL - 18

SP - 2095

EP - 2103

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -